ABSTRACT
Asthma is currently a worldwide problem, with increasing prevalence in both
?r children and adults; a prevalence rate of 5 - 10% has been reported for Nigeria.
The pathophysiological features of the disease are bronchoconstriction, airway
hyperresponsiveness and chronic inflammation. Drugs used in the management
include bronchodilators which are short-term relievers and anti-inflammatory
drugs which are long-term controllers. Despite the availability of oral and inhaled
medications, the prevalence of asthma is on the rise. The challenge of developing
b
new effective, safe and long lasting antiasthmatic drugs from natural products
appears inevitable. The leaves of Asystasia gangetica L. (T). Anderson sub species
micrantha (Nees) Ensermu (Acanthaceae), a traditional anti-asthma remedy, offer
?
great potential for the development of a novel anti-asthmatic agent. The leaves
have been shown to possess antihistaminic, bronchospasmolytic and antiinflammatory
properties. The aim of this research was to isolate and
pharmacologically characterize the anti-asthmatic constituent of the leaves of this
plant using bioactivity-guided fractionation of the leaf extract.
The leaves of A. gangetica were sun dried in open air for 48 h and pulverized to
coarse powder. The leaf powder was extracted by cold maceration in 100%
methanol for 48 h. The extract obtained was concentrated in a rotary evaporator
under reduced pressure to afford the methanol extract (ME). The median lethal
?,
dose (LDSd) of ME was determined in mice using the intraperitoneal route. The
ME was fractionated in a silica gel (70 - 230 mesh) column successively eluted
. . .
Vlll
with hexane: ethylacetate (7:3) and methanol (100%) to obtain fractions A, B and
C. Screening of the three fractions for bronchospasmolytic activity using
inhibition of histamine induced contraction of the guinea pig trachea and
relaxation of pre-contracted trachea (pathological tissue) as bioactivity-guides
showed that fraction B exhibited the greatest effect in both tests. Based on the
results, fraction B was hrther separated using gradient solvent mixtures of hexane:
ethyl acetate (9.5:0.5, 9:1, 8:2, 7:3, 6:4, 5:5, 0:l) to obtain eight fractions (Fr I, Fr
11, Fr 111, Fr IV, Fr V, Fr VI, Fr VII, Fr VIII). Activity-guided tests on these
b
fractions revealed greatest potency in Fr VIII, which on chromatographic
separation successively eluted with petroleum ether: ethyl acetate (7:3) and
ethylacetate (100%) yielded two fractions (Fr 1 and Fr 2). Fr 2 yielded a brown ' amorphous powder AG-1 which at 0.4 mg/ml completely inhibited the
contractions of the guinea pig trachea induced by histamine. The methanol extract
(ME), fraction B, Fr VIII and Fr 2 were subjected to phytochemical analysis for
identification of constituents. The effect of the extract and fractions (200 and 400
mgkg) on systemic acute inflammation was studied in rats using the paw edema
induced by carrageenan. Also, the effect of the extract and fractions (400 mg/kg)
on carrageenan-induced leukocyte infiltration into the pleural cavity as well as
pleural exudate formation was evaluated in rats. The data obtained was analysed
using One Way Analysis of Variance in SPSS Version 1 1. +
Phytochemical tests showed that the ME tested positive to alkaloids, glycosides,
saponins, reducing sugars, terpenes and carbohydrate. Fraction B gave positive
reactions for flavonoids and terpenes while Fr VIII tested positive to flavonoids,
terpenes and steroids. Fr 2 gave positive reactions for terpenes and steroids. The
9 intraperitoneal median lethal dose (LDSo) of ME in mice was estimated to be
greater than 5,000 mglkg. In the isolated tissue tests, the ME, Fr B, Fr VIII and
AG-1 exhibited varying degrees of dose-dependent inhibition of contractions of
the guinea pig trachea induced by histamine. The ME and the fractions also
relaxed the guinea pig trachea pre-contracted with histamine. In the whole animal
experiments, ME, Fr B and Fr VIII significantly (P
, E & CHIOMA, A (2021). Pharmacological Characterization Of The Antiasthmatic Constituent Of The Leaves Of Asystasia Gangetica (L.) Anderson (ACANTHACEAE). Afribary. Retrieved from https://tracking.afribary.com/works/pharmacological-characterization-of-the-antiasthmatic-constituent-of-the-leaves-of-asystasia-gangetica-l-anderson-acanthaceae
, EZIKE and ADAOBI CHIOMA "Pharmacological Characterization Of The Antiasthmatic Constituent Of The Leaves Of Asystasia Gangetica (L.) Anderson (ACANTHACEAE)" Afribary. Afribary, 02 May. 2021, https://tracking.afribary.com/works/pharmacological-characterization-of-the-antiasthmatic-constituent-of-the-leaves-of-asystasia-gangetica-l-anderson-acanthaceae. Accessed 24 Nov. 2024.
, EZIKE, ADAOBI CHIOMA . "Pharmacological Characterization Of The Antiasthmatic Constituent Of The Leaves Of Asystasia Gangetica (L.) Anderson (ACANTHACEAE)". Afribary, Afribary, 02 May. 2021. Web. 24 Nov. 2024. < https://tracking.afribary.com/works/pharmacological-characterization-of-the-antiasthmatic-constituent-of-the-leaves-of-asystasia-gangetica-l-anderson-acanthaceae >.
, EZIKE and CHIOMA, ADAOBI . "Pharmacological Characterization Of The Antiasthmatic Constituent Of The Leaves Of Asystasia Gangetica (L.) Anderson (ACANTHACEAE)" Afribary (2021). Accessed November 24, 2024. https://tracking.afribary.com/works/pharmacological-characterization-of-the-antiasthmatic-constituent-of-the-leaves-of-asystasia-gangetica-l-anderson-acanthaceae